Skip to Content

Generic Ryzolt Availability

Ryzolt is a brand name of tramadol, approved by the FDA in the following formulation(s):

RYZOLT (tramadol hydrochloride - tablet, extended release;oral)

  • Manufacturer: PURDUE PHARMA
    Approval date: December 30, 2008
    Strength(s): 100MG, 200MG, 300MG

All of the above formulations have been discontinued.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Ryzolt. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

  • Cross-linked high amylose starch for use in controlled-release pharmaceutical formulations and processes for its manufacture
    Patent 6,607,748
    Issued: August 19, 2003
    Inventor(s): Vincent; Lenaerts & Roland Herwig Friedrich; Beck & Elsie; Van Bogaert & Francois; Chouinard & Reiner; Höpcke & Cyril; Désévaux
    The present invention relates to a novel form of cross-linked high amylose starch and processes for its manufacture. Such cross-linked high amylose starch is useful as an excipient in a controlled-release pharmaceutical formulation when compressed with pharmaceutical agent(s) in a tablet. Such cross-linked high amylose starch is prepared by (a) cross-linking and chemical modification of high amylose starch, (b) gelatinization, and (c) drying to obtain a powder of said controlled release excipient. In a preferred embodiment, such cross-linked high amylose starch is prepared in the following steps: (1) granular cross-linking and additional chemical modification (e.g., hydroxypropylation) of high-amylose starch; (2) thermal gelatinization of the starch from step (1); and (3) drying the starch from step (2) to yield a powder capable of being used as a controlled release excipient.
    Patent expiration dates:
    • June 29, 2020
      Drug product
  • Sustained-release tramadol formulations with 24-hour efficacy
    Patent 7,988,998
    Issued: August 2, 2011
    Inventor(s): Lenaerts; Vincent & Ouadji-Nijki; Patricia Laure & Bacon; Jonathan & Ouzérourou; Rachid & Gervais; Sonia & Rahmouni; Miloud & Smith; Damon
    Assignee(s): Labopharm Inc. Labopharm Europe Limited Labopharm (Barbados) Limited
    A sustained-release tramadol formulation oral administration is provided which, upon initial administration of one dose, provides an analgesic effect within 2 hours, which analgesic effect continues for at least 24 hours after administration.
    Patent expiration dates:
    • October 27, 2023
      Drug product


Drug PatentA drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation.
Drug ExclusivityExclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant.